Program Detail

Modality
Program #
Program
indication
Presentation

Source
Respiratory syncytial virus (RSV) vaccine

Last program update Dec 06, 2018

Source
Cytomegalovirus (CMV) vaccine

Last program update Mar 06, 2019

Source
Human metapneumovirus and \nparainfluenza virus 3 (hMPV+PIV3) vaccine

Last program update Feb 12, 2019

Source
Varicella zoster virus (VZV) vaccine

Last program update Dec 06, 2018

Source
Influenza H10N8 vaccine

Last program update Dec 06, 2018

Source
Influenza H7N9 vaccine

Last program update Dec 06, 2018

Source
Zika vaccine

Last program update Mar 06, 2019

Source
Chikungunya vaccine

Last program update Dec 06, 2018

Source
Personalized Cancer Vaccine (PCV) \n\iSolid tumors/i

Last program update Mar 06, 2019

Source
KRAS vaccine \n\iCRC, NSCLC, pancreatic cancer/i

Last program update Dec 06, 2018

Source
OX40L \n\iSolid tumors/lymphoma/i\n\iAdvanced ovarian carcinoma/i

Last program update Mar 06, 2019

Source
OX40L+IL23+IL36γ \n\iSolid tumors/lymphoma/i

Last program update Mar 06, 2019

Source
IL12 \n\iSolid tumors/i

Last program update Mar 06, 2019

Source
VEGF-A \n\iMyocardial ischemia/i

Last program update Dec 06, 2018

Source
Antibody against Chikungunya virus

Last program update Mar 06, 2019

Source
Relaxin \n\iHeart failure/i

Last program update Dec 06, 2018

Source
α-GAL \n\iFabry disease/i

Last program update Dec 06, 2018

Source
MUT \n\iMethylmalonic acidemia (MMA)/i

Last program update Mar 06, 2019

Source
PCCA+PCCB \n\iPropionic acidemia (PA)/i

Last program update Dec 06, 2018

Source
PAH \n\iPhenylketonuria (PKU)/i

Last program update Dec 06, 2018